← Leaderboards
Lukas Michael Carter
Sloan-Kettering Inst Can Research
$178,734
Attributed
$178,734
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $63.7K · FY2017–19$100K$75K$50K$25K$0
'17
'18
'19
Funding mix
By agency
NIH$178,734 · 1
By mechanism
F32$178,734 · 1
Top collaborators
No co-investigators on record.
Most similar at Sloan-Kettering Inst Can Research
Same institution · by research overlap
- Robert V Farese$28,829,369
- Craig B Thompson$56,520,903
- Richard N Kolesnick$17,601,323
- Michael Stephen Glickman$43,477,930
- Jason S Lewis$26,024,327
Others in their field
Other Emerging Leaders on “Affect”
- Chanza Baytop · Westat, Inc.$271,217,917
- Leonard Freedman · Leidos Biomedical Research, Inc.$62,378,387
- Jennifer Marie Suga · Kaiser Foundation Research Institute$29,218,159
- Lynn Briscoe · Leidos Biomedical Research, Inc.$27,788,199
- George Robert Painter · University Of Alabama At Birmingham$27,619,145
- Jessica Brooke Langbaum · Banner Health$22,633,312
Research focus
AffectAffinityAnalogAnalytical ChemistryAnimal-Assisted TherapyAnticancer ResearchAreaBaseBiodistributionBreast Cancer ModelBreast Cancer TherapyBreast Cancer TreatmentCancer BiologyCancer CellCancerousCareer ChoiceCareer DevelopmentCell MembraneCellular MembraneChelating AgentsCleaved CellClinicClinical ApplicationAcidity
Grant awards (3)
Development of a Novel Peptide Platform for Targeted PET Imaging and Radiotherapy of Breast Cancer$63,746
F32 · FY2019 · EB · contact PI
Development of a Novel Peptide Platform for Targeted PET Imaging and Radiotherapy of Breast Cancer$58,654
F32 · FY2018 · EB · contact PI
Development of a Novel Peptide Platform for Targeted PET Imaging and Radiotherapy of Breast Cancer$56,334
F32 · FY2017 · EB · contact PI